在高水平人群中,单剂量的Rona治疗药物RN0361将三甘酸酯减少69%,没有严重的副作用。 A single dose of Rona Therapeutics' RN0361 reduced triglycerides by up to 69% in people with high levels, with no serious side effects.

罗纳治疗学报告,在2025年美国心脏协会科学会议上,RN0361,即针对Apolipoprotein C3的SiRNA疗法,第一阶段试验结果为RN0361。 Rona Therapeutics reported Phase 1 trial results for RN0361, an siRNA therapy targeting Apolipoprotein C3, at the 2025 American Heart Association Scientific Sessions. 在使用高三甘酸酯的人中,单剂量导致持续减少至少6个月 -- -- ApoC3和三甘酸酯分别高达93%和69% -- -- 以及有害的脂质大幅下降。 A single dose in people with high triglycerides led to sustained reductions—up to 93% in ApoC3 and 69% in triglycerides—for at least six months, along with significant drops in harmful lipoproteins. 治疗效果良好,只有轻微的、暂时的副作用。 The treatment was well-tolerated, with only mild, temporary side effects. 没有发生严重不利事件。 No serious adverse events occurred. 数据支持将RN0361推进到第2阶段,对重度高血压性贫血进行试验,这种疾病与胰腺炎和心脏病有关。 The data support advancing RN0361 into Phase 2 trials for severe hypertriglyceridemia, a condition linked to pancreatitis and heart disease.